The Knee Bursitis Market is expected to grow at a CAGR of 7.1% during the forecast period
2017-2023.
The Global Knee Bursitis Market is expecting a sound growth in the coming future owing to
the increasing prevalence of bone-related diseases and favorable reimbursement policies.
Mostly all diabetic patients suffer from some or the other knee bursitis. According to findings
from the WHO in 2014, approximately 422 million people reported suffering from diabetes.
Due to the increasing diabetic population across the globe, there is a significant increase in
the number of people with knee bursitis. Additionally, increasing geriatric population and
increasing healthcare expenditure have fuelled the growth of the market. On the other
hand, strict regulatory rules and the high cost of the treatment methods may slow the
growth of the market during the forecast period.
Key players in the global knee bursitis market:
Some of the major players in this market are Novartis AG, Pfizer Inc, Amgen Inc, AVEO
Pharmaceuticals Inc, Bayer AG, Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck &
Co., Inc, Merrimack Pharmaceuticals Inc, Oncolys BioPharma Inc, United Therapeutics Corp
and others.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/5408 .
Segments:
The Global Knee Bursitis Market has been segmented on the basis of diagnosis, treatment,
and end users.
On the basis of the diagnosis, the Global Knee Bursitis Market is segmented into imaging
tests and others. Imaging tests are further segmented into X-ray, MRI, ultrasound, and
others.
Based on the treatment, it is segmented medication, therapy, surgery, and others.
Medication is sub-segmented into antibiotic treatment and others. Others segment includes
corticosteroid injection and others.
On the basis of the end users, the market is segmented into hospitals & clinics, diagnostic
centers, research centers, academic institutes, and others.
Regional analysis
The Americas accounted for the major share of the market owing to the presence of a huge
population of patients suffering from bone related problems or joint pains, high healthcare
expenditure, well-developed technology, and the presence of the leading players.
Furthermore, rising government support for the development of the advanced devices and
well-developed healthcare sector has boosted the growth of the knee bursitis market in the
Americas.
Europe accounted for the second largest market for the knee bursitis, which is followed by
Asia Pacific. Increasing prevalence of the knee bursitis, diabetes, and huge healthcare
spending are the major driving factors that have boosted the market growth. Additionally,
the healthcare expenditure in this region is also rising. People and healthcare organizations
in this region are able to afford the high cost of the devices, which is driving the growth of
the market. Furthermore, increasing government support and funding for the development
and improvement of the treatments have fuelled the growth of the market.
The Asia Pacific is the fastest growing knee bursitis market. Increasing need for better
devices, rapidly improving technology, and the presence of huge patient pool is driving the
growth of the market in this region.
The Middle East & Africa holds the least share of the market owing to the presence of poor
and slow developing countries, especially, in the African region. The major driving factors
for the growth of the Middle East & African knee bursitis market are increasing aging
population and increasing number of diabetic patients.
Table of Content
1. Report Prologue
2. Market Introduction